Join us for our SUO Fellowship Virtual Open House on January 13, 2026, 7-8 PM EST @ssjoshi.bsky.social @emoryuroonc.bsky.social . Register here: zoom.us/meeting/regi...

My thanks to my #EmoryUrology family and the teams at #Apple and @hey.epic.com for helping us tell the @emoryhealthcareatl.bsky.social story of how clinician well-being is being prioritized through the use of great technology www.apple.com/healthcare/s...

Healthcare - Success Stories

Read the success stories of how health organizations around the world use Apple technology to reduce clinician burnout and deliver personalized care.

apple.com

Congratulations to our very own @tgoodstein.bsky.social for being awarded the 2025 Society of Urologic Oncology #CGOncology #NMIBC Fellowship Grant at #AUA2025 @ssjoshi.bsky.social @drnarayan.com

Thanks again to Tommy Korn and everyone at Sharp Healthcare for hosting a fantastic Spatial Computing Health Care Summit - awesome to see all the amazing things people have been doing with Apple #VisionPro & to share some of what we’ve been able to do with our partners at #KarlStorz #SharpSpatial

“Grateful to be at #SWIU surrounded by incredible women—friends, colleagues, and mentees. Inspired by the exchange of ideas and learning about topics that truly empower us to lead fulfilled and successful lives. Here’s to growth, community, and innovation! 🩷 #WomenInUrology” @emoryuroonc.bsky.social

Interested in learning about Emory’s #SUO fellowship? 📆 Join us for a virtual open house on Thursday, Jan 16th from 7-8 PM EST DM or email us if you’re interested -we’ll send you a link! @ssjoshi.bsky.social @valentinagrajales.bsky.social @tgoodstein.bsky.social @winshipatemory.bsky.social

Proud of our first @emoryuroonc.bsky.social SUO fellow #TaylorGoodstein making a splash in RCC research at the #SUO24 Winter Meeting @ssjoshi.bsky.social @jackiebrownmd.bsky.social

Packed house at SUO2024 for NMIBC discussion. Our thought leader @drnarayan.com from @emoryuroonc.bsky.social @winshipatemory.bsky.social Ongoing challenge: how do we manage high risk NMIBC? Especially those with variants? @valentinagrajales.bsky.social

Interesting study…only 56% OS at 5 years strikes me as lower than I would expect; by comparison an 80% 5 year OS was observed in the ph3 nado trial for BCG unresponsive pts (76% in CIS only patients, 86% in papillary dz). Worth calling out the 53% grade 3 AE rate as well… @emoryuroonc.bsky.social

Yüksel Ürün@yukselurun.bsky.social · 2y ago

☢️💊💉Trimodality therapy offers hope for recurrent T1 bladder cancer after BCG failure! ✅ 3-year freedom from cystectomy: 88% ✅ 3-year OS: 69% 🔷monitoring is key. #BladderCancer #Oncology @oncoalert.bsky.social @oncbrothers.bsky.social @achoud72.bsky.social

Urology residents of @bsky.app , let us know if you will be in Dallas for SUO 2024 and would like to chat about the @emoryuroonc.bsky.social SUO Fellowship! @drnarayan.com @valentinagrajales.bsky.social

@emoryuroonc.bsky.social welcome to Bluesky!

Join the conversation on all things #bladdercancer #kidneycancer #prostatecancer and help grow the GU Oncology Starter Pack go.bsky.app/6NdMXmY

The non-coding RNA based classifier identifies urothelial carcinomas harboring less aggressive tumor biology associated with favorable outcomes after radical cystectomy doi.org/10.1111/bju....

A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy

Objective To further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non-coding RNA (lncRNA)-based genomic profiling has suggested utility in i...

doi.org